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abstRact
IntroductIon: Difficulty in identifying patients who are at 
risk for hepatitis B virus (HBV) reactivation makes it import­
ant to screen for HBV before initiating immunosuppressive 
therapy. The aim of this study was to investigate screening 
procedures for HBV infection before initiation of immuno­
suppressive therapy and to explore HBV treatment strat­
egies. 
Methods: All Danish units of haematology, oncology, der­
matology, rheumatology and gastroenterology using immu­
nosuppressive agents were invited to fill out a question­
naire for The Danish Database for Hepatitis B and C. 
results: A total of 28 (53%) of the 53 included units an­
swered the questionnaire; of which 25 (89.3%) had a guide­
line regarding screening for HBV serological markers prior 
to immunosuppressive therapy, but only ten (37%) had a 
guideline that is in line with the joint guidelines from the 
national Danish Societies of Infectious Diseases and Gastro­
enterology and Hepatology. Nineteen (76%) units had a 
strategy regarding treatment for reactivation before initiat­
ing immunosuppressive therapy in case of positive HBV ser­
ology. It was not possible to determine the number of HBV 
reactivations as this was not registered in the ICD­10 sys­
tem. The Danish Medicines Agency had one report of reacti­
vation. 
conclusIons: A minority of the units had screening guide­
lines for HBV reactivation that were in line with the guide­
lines of the national scientific societies. Screening in accord­
ance with these recommendations should be a goal for all 
Danish units in order to prevent HBV reactivation. 
FundIng: none. 
trIal regIstratIon: not relevant.
Hepatitis B virus (HBV) infection is a major global health 
problem: approximately 240 million individuals are 
chronically infected, and according to the World Health 
Organization (WHO) approximately 686,000 individuals 
die annually due to hepatitis B [1]. Reactivation of HBV 
infection is a well­known complication in patients receiv­
ing immunosuppressive therapy [2]. HBV reactivation is 
characterised by rising serum HBV DNA levels followed 
by rising alanine transaminase. The increase in HBV rep­
lication frequently occurs within weeks or months after 
immunosuppression, but sometimes it occurs even  
within the treatment period. Immune reconstitution 
days or weeks after dose reduction or finished treat­
ment may lead to a flare­up of hepatitis B manifested as 
hepatocellular injury due to alanine transaminase eleva­
tion [3]. The clinical presentation of the disease is highly 
variable ranging from a subclinical, asymptomatic course 
to fulminant hepatitis, liver failure and death [3]. Reacti­
vation is observed in different settings and can therefore 
be difficult to diagnose. It is associated with the use of 
monoclonal antibodies, chemotherapy, steroids and 
 immunosuppression in the context of solid organ trans­
plantation [4­6]. Reactivation is most commonly ob­
served in patients receiving chemotherapy for haemato­
logical malignancies [7], but it is also frequent in patients 
treated for diseases in the specialities of dermatology, 
rheumatology, gastroenterology, oncology and nephrol­
ogy [8]. Prophylactic anti­viral therapy has been shown 
to be effective in preventing HBV reactivation [9, 10]. 
Nevertheless, inconsistency in guideline recommenda­
tions and the lack of HBV screening before the initiation 
of immunosuppressive treatment have led to successive 
reports of fatal reactivation [11]. 
As a result of the increasing use of aggressive im­
munosuppressive agents, a growing number of interna­
tional migrants, and the difficulty of identifying patients 
in HBV high­risk groups, HBV reactivation has also be­
come a growing problem in low­endemic countries. 
The aim of this study was to investigate screening 
procedures for HBV infection before the initiation of im­
munosuppressive therapy, and to explore the use of 
strategies for further treatment in patients with a HBV 
serology indicating ongoing or previous HBV infection 
who are undergoing immunosuppressive therapy in a 
HBV­low­endemic country, such as Denmark. 
mEthOds 
From March to May 2014, all Danish units in the speci­
alities of haematology, oncology, dermatology, rheuma­
tology and gastroenterology were identified through 
medinfo.dk and the SKS browser (the Healthcare Classif i­
cation System – a collection of International, Nordic and 
Danish classifications). The units were included in the 
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study owing to their use of immunosuppressive agents 
on a daily basis (e.g. alemtuzumab, azathioprine, cyclo­
phosphamide, steroids, methotrexate, rituximab and 
TNF inhibitors). 
Phone calls to the above­mentioned hospital units 
identified the email addresses of the head physicians of 
the departments. A questionnaire consisting of eleven 
questions was created and emailed to all head phys­
icians of the included units on behalf of the Danish 
Database for Hepatitis B and C (DANHEP) [12]. The ques­
tionnaire was accompanied by an introductory letter ex­
plaining the issue of HBV reactivation associated with 
the use of immunosuppressive agents. E­mails with 
questionnaires and introductory letters were initially 
sent in the beginning of June 2014 and then twice more, 
the latest in November 2014. If a unit did not return the 
questionnaire by the end of November 2014, unit staff 
was politely asked by phone to participate in the study. 
It was decided to keep the participating units anony m­
ised and to refer only to the medical speciality of the 
units. 
As part of this study, we attempted to determine 
the exact number of reactivations, but this was unfor­
tunately not possible because the units included in the 
study had not registered the number of reactivations 
through the International Classification of Diseases, 
tenth edition (ICD­10) system. We therefore contacted 
the Danish Medicines Agency (the supreme pharma­
ceutical authority in Denmark), who used their database 
to determine that there had been only one report of re­
activation of HBV as a side effect to immunosuppressive 
therapy.     
According to Danish legislation on research ethics, 
the approval of the Research Ethics Committee was not 
needed as this was a questionnaire­based study. This 
study was based on questionnaires answered by hospital 
departments rather than individual patients. 
Trial registration: not relevant. 
REsUlts 
A total of 59 potential units were traced of which six 
were excluded: four because they were not offering 
treatment relevant to the current study, and two be­
cause they were unable to answer the questionnaire due 
to technical problems. In total, 53 units were included. 
Of these 53 units, nine were haematology units, ten 
were oncology units, four were dermatology units, 13 
were gastroenterology units and 17 were rheumatology 
units. 
Of the 53 units approached, 28 (53%) chose to par­
ticipate in the study, of which five (18%) were haema­
tology units, four (14%) were oncology units, three 
(11%) were dermatology units, seven (25%) were gastro­
enterology units and nine (32%) were rheumatology 
units (Figure 1). 
Of the 25 approached but not participating units 
(47%), four were haematology units (16%), six oncology 
units (24%), one was a dermatology unit (4%), six were 
gastroenterology units (24%) and eight were rheuma­
tology units (32%).       
A total of 25 (89%) of the participating units had a 
guideline on screening of HBV serological markers be­
fore the initiation of immunosuppressive therapy. It 
must be expected that if a unit has guidelines on screen­
ing for HBV, these guidelines will be followed by the spe­
cialists working at that unit. Only ten (36%) of the guide­
lines were in line with the joint guidelines from the 
Danish Society of Infectious Diseases and the Danish 
Society of Gastroenterology and Hepatology (hereafter: 
“national societies”), which recommend screening for 
HBsAg, anti­HBs and anti­HBc before initiation of immu­
nosuppressive therapy in Denmark [13].
Regarding the measurement of specific HBV sero­
logical markers (question answered by 27 units), four 
(15%) units screened for HBsAg only; ten (37%) units 
screened for HBsAg, anti­HBs and anti­HBc; one (4%) 
unit screened for HBV­DNA and anti­HBc; three (11%) 
units screened for HBsAg and anti­HBc; five (18%) units 
screened for HBsAg and anti­HBs; and four (15%) units 
(all oncology units) did not provide screening for any 
HBV serological markers before the initiation of immu­
nosuppressive therapy. 
Of the responding units, 25 (89%) answered the 
question regarding “a strategy” on further treatment of 
patients with positive HBV serological markers (positive 
HBsAg, anti­HBc or anti­HBs in non­vaccinated individu­
als) during and after immunosuppressive therapy. A to­
tal of 19 (76%) of these units had a strategy for further 
FigURE 1
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treatment. A “strategy” included either a unit­approved 
guideline describing the treatment and prophylaxis of 
the patient with antiviral therapy during and after the 
immunosuppressive therapy or a guideline directing the 
patient to a department of infectious diseases or med­
ical gastroenterology for further treatment and anti­viral 
prophylaxis.     
discUssiOn
In this nationwide Danish questionnaire study, we re­
vealed that the majority (89%) of the 28 participating 
units did follow HBV screening procedures before the  
initiation of immunosuppressive therapy; 89% is a rela­
tively high share, but only ten (37%) of these units had  
a guideline that was in line with the recommendations 
published by the national societies. A future goal should 
therefore be that all units in Denmark follow the same 
national screening procedures before initiating immuno­
suppressive therapy to ensure the best possible treat­
ment for the patients. This could be improved by add­
itional collaboration between the national scientific 
societies that use these immunosuppressive agents. 
None of the oncology units participating in this 
study screened for HBV markers before the initiation of 
immunosuppressive therapy. This could be because the 
Danish Society of Clinical Oncology has been influenced 
by The American Society for Clinical Oncology (ASCO), 
which in 2010 published a clinical opinion stating that 
there is insufficient evidence on this subject to deter­
mine the benefits and harms of universal screening for 
HBV in cancer patients receiving immunosuppressive 
therapy. Physicians should, nevertheless, be careful with 
“high­risk” patients [14]. It is difficult, however, to be 
careful when suspected risk factors of HBV infection are 
not always apparent. In addition, the patient may not 
know the risk factors or even remember high­risk behav­
iour and, furthermore, the provider may not ask about 
risk factors or not even be aware of them [2]. However, 
in 2015 ASCO published a new clinical opinion recom­
mending that medical providers screen for HBV before 
starting anti­CD20 therapy or haematopoietic cell trans­
plantation. Additionally, they should also screen patients 
with risk factors for HBV infection [15].
In general, there is inconsistency between guideline 
recommendations in this area. The European Association 
for the Study of the Liver, the Asian­Pacific Association 
for the Study of the Liver and The US Centers for Disease 
Control and Prevention recommend universal HBV 
screening prior to initiation of immunosuppressive ther­
apy, whereas the American Association for the Study of 
Liver Diseases and the National Comprehensive Cancer 
Network recommend screening of patients with risk fac­
tors [8].
Denmark is an HBV­low­endemic country with an 
estimated HBV prevalence of 0.24% [12]. The majority of 
HBV infected individuals in Denmark are immigrants 
[16]. However, cases with a fatal outcome of reactiva­
tion also do occur in native Danish individuals with no 
suspected risk factors for HBV infection. This shows that 
although a country is low endemic regarding HBV infec­
tions and the majority of infected individuals are immi­
grants, it is still not possible to determine exactly which 
patients are at “high risk” of experiencing HBV reactiva­
tion. Thus, a screening strategy directed towards high­
risk persons, e.g., patients migrated from HBV­endemic 
countries to Denmark, is insufficient. In addition, pro­
viders may often forget to ask about risk factors as HBV 
is rarely encountered in native Danes. Therefore, uni­
versal screening for HBV markers is the first critical step 
towards prevention. As recently presented by Perrillo et 
al in JAMA, a barrier to universal HBV screening is the  
misperception that HBV reactivation rarely occurs in 
Western countries, and that all who are HBV­infected 
have recognisable risk factors [2]. Together with incon­
sistent guideline recommendations in this area, these 
barriers play a part in the continuous occurrence of HBV 
reactivation due to failure to screen patients for HBV be­
fore initiating immunosuppressive therapy. This is unfor­
tunate as HBV reactivation is easily prevented with pro­
phylactic antiviral therapy, which does not interact with 
medications used for immunosuppressive therapy. 
Another reason to support universal HBV screening 
is the possible interruption of chemotherapy that may 
follow from reactivation, and which may potentially lead 
to a poorer cancer therapy­related outcome [17]. 
A total of 19 (68%) of the responding 28 units had a 
guideline on further treatment and prophylaxis of pa­
tients with positive HBV serological markers – including 
referring the patient to a department of infectious dis­
eases or a department of medical gastroenterology for 
further evaluation and treatment. In the present study, 
we did not investigate prophylactic antiviral procedures 
in departments of infectious diseases; thus, it was not 
possible to determine whether lamivudine, tenofovir or 
entecavir were used as first­line prophylactic antiviral 
therapy in Denmark. Today, entecavir or tenofovir is re­
commended as first­line treatment [18, 19].
It is not clear for how long antiviral therapy should 
be continued. In patients receiving rituximab, reactiva­
tion can occur late, which is the reason why the Euro­
pean Association for the Study of the Liver (EASL) rec­
ommends continuing antiviral prophylaxis during and up 
to 12 months after the completion of immunosuppres­
sive therapy [18]. Very few of the participating units had 
a guideline on the duration of prophylactic antiviral 
therapy, and none of the Danish Societies representing 
the five types of units included had any recommenda­
tions regarding this issue. 
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A strength of this study is that we reached out to 
the entire relevant healthcare sector to gather informa­
tion regarding HBV screening before the initiation of im­
munosuppressive therapy, but it should be noted that 
only 28 (53%) of the contacted units chose to respond. 
Moreover, only 25 of 28 (89%) participating units had a 
screening guideline. We do not know why so many units 
chose not to participate, but we presume this might be 
due to competing demands for the physicians’ time. 
Furthermore, it is difficult to know if the specialists ac­
tually adhere to the guidelines set forth by the units 
[20]. 
According to The Danish Medicines Agency, there 
had been only one report of HBV reactivation notified as 
a side effect to immunosuppressive therapy. Neverthe­
less, The Danish Medicines Agency concluded that far 
from everything is reported to them, including rare side 
effects such as HBV reactivation.  
cOnclUsiOns 
This nationwide questionnaire study demonstrated that 
in an HBV­low­endemic country such as Denmark, very 
few units have guidelines that are in line with the joint 
guidelines of the national scientific societies of infec­
tious diseases and gastroenterology and hepatology, 
and not all units have a treatment strategy for HBV reac­
tivation.
It is important to increase physicians’ awareness of 
HBV reactivation and to implement universal screening 
for HBV before the initiation of immunosuppressive 
therapy both in high­endemic and in low­endemic coun­
tries, because of the potential severity of reactivation 
and the efficiency of prophylactic antiviral therapy.
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